WF
WST icon

Welch & Forbes’s West Pharmaceutical WST Stock Holding History

Welch & Forbes’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Sell
3,223
-190
-6% -$58.1K 0.01% 217
2026
Q1 		$855K Buy
3,413
+552
+19% +$137K 0.01% 234
2025
Q4 		$787K Sell
2,861
-146
-5% -$39.9K 0.01% 243
2025
Q3 		$789K Sell
3,007
-1,139
-27% -$277K 0.01% 245
2025
Q2 		$907K Sell
4,146
-2,988
-42% -$639K 0.01% 228
2025
Q1 		$1.6M Sell
7,134
-1,337
-16% -$368K 0.02% 195
2024
Q4 		$2.77M Sell
8,471
-656
-7% -$206K 0.04% 159
2024
Q3 		$2.74M Buy
9,127
+343
+4% +$105K 0.03% 161
2024
Q2 		$2.83M Buy
8,784
+2,646
+43% +$935K 0.04% 160
2024
Q1 		$2.43M Buy
6,138
+2,404
+64% +$889K 0.03% 176
2023
Q4 		$1.31M Buy
3,734
+545
+17% +$193K 0.02% 211
2023
Q3 		$1.2M Buy
3,189
+389
+14% +$150K 0.02% 212
2023
Q2 		$1.07M Buy
2,800
+1,884
+206% +$673K 0.02% 225
2023
Q1 		$317K Buy
+916
New +$268K 0.01% 325

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Welch & Forbes's WST Position: Q2 2026 in Review

Welch & Forbes reduced its West Pharmaceutical (WST) stake by 5.6% in Q2 2026, selling an estimated $58.1K and leaving 3,223 shares worth $1.16M. The position accounts for 0.01% of the portfolio, ranked #217.

Welch & Forbes first reported a position in WST in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.83M in Q2 2024. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Welch & Forbes held 3,223 shares of West Pharmaceutical worth $1.16M as of Q2 2026.
  • Welch & Forbes sold 190 West Pharmaceutical shares in Q2 2026, an estimated $58.1K.
  • West Pharmaceutical made up 0.01% of Welch & Forbes's portfolio in Q2 2026, its #217 holding.
  • Welch & Forbes first reported a position in West Pharmaceutical in Q1 2023 and has held it in 14 quarters since.
  • Welch & Forbes's West Pharmaceutical position peaked at $2.83M in Q2 2024.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Welch & Forbes's 13F filing for Q2 2026, filed 30 Jul 2026.